189 related articles for article (PubMed ID: 24493623)
1. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.
Wang HW; Yang SH; Huang GD; Lin JK; Chen WS; Jiang JK; Lan YT; Lin CC; Hwang WL; Tzeng CH; Li AF; Yen CC; Teng HW
J Cancer Res Clin Oncol; 2014 Apr; 140(4):561-71. PubMed ID: 24493623
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
3. CIP2A is a predictor of poor prognosis in colon cancer.
Teng HW; Yang SH; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Chen PC; Lan YT; Lin CC; Hsu YN; Wang HW; Chen KF
J Gastrointest Surg; 2012 May; 16(5):1037-47. PubMed ID: 22328001
[TBL] [Abstract][Full Text] [Related]
4. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
5. Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells.
Cristóbal I; Manso R; Rincón R; Madoz-Gúrpide J; Caramés C; Rojo F; García-Foncillas J
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1249-50. PubMed ID: 24828260
[No Abstract] [Full Text] [Related]
6. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression.
Wiegering A; Pfann C; Uthe FW; Otto C; Rycak L; Mäder U; Gasser M; Waaga-Gasser AM; Eilers M; Germer CT
PLoS One; 2013; 8(10):e75292. PubMed ID: 24098375
[TBL] [Abstract][Full Text] [Related]
7. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
[TBL] [Abstract][Full Text] [Related]
9. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
[TBL] [Abstract][Full Text] [Related]
10. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
11. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
[TBL] [Abstract][Full Text] [Related]
12. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression.
Guo B; Wu S; Zhu X; Zhang L; Deng J; Li F; Wang Y; Zhang S; Wu R; Lu J; Zhou Y
EMBO J; 2020 Jan; 39(1):e102190. PubMed ID: 31755573
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
Lattanzio L; Milano G; Monteverde M; Tonissi F; Vivenza D; Merlano M; Lo Nigro C
Anticancer Drugs; 2016 Jul; 27(6):533-9. PubMed ID: 26982238
[TBL] [Abstract][Full Text] [Related]
14. Role of CIP2A in the antitumor effect of bortezomib in colon cancer.
Ding Y; Wang Y; Ju S; Wu X; Zhu W; Shi F; Mao L
Mol Med Rep; 2014 Jul; 10(1):387-92. PubMed ID: 24789441
[TBL] [Abstract][Full Text] [Related]
15. Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.
Khanna A; Thoms JAI; Stringer BW; Chung SA; Ensbey KS; Jue TR; Jahan Z; Subramanian S; Anande G; Shen H; Unnikrishnan A; McDonald KL; Day BW; Pimanda JE
Mol Cancer Res; 2020 May; 18(5):709-722. PubMed ID: 32079743
[TBL] [Abstract][Full Text] [Related]
16. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
[TBL] [Abstract][Full Text] [Related]
18. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.
Allen JE; Gallant JN; Dicker DT; Amin S; Irby RB; Sharma AK; El-Deiry WS
PLoS One; 2013; 8(3):e59380. PubMed ID: 23555026
[TBL] [Abstract][Full Text] [Related]
19. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.
Lei N; Peng B; Zhang JY
Oncol Rep; 2014 Oct; 32(4):1689-94. PubMed ID: 25109354
[TBL] [Abstract][Full Text] [Related]
20. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy.
Chen KF; Yen CC; Lin JK; Chen WS; Yang SH; Jiang JK; Lan YT; Lin CC; Yu HC; Hsu HM; Lin WL; Teng HW
BMC Cancer; 2015 Apr; 15():301. PubMed ID: 25896895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
